Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UroGen Pharma Ltd. Director's Dealing 2024

Feb 2, 2024

32312_dirs_2024-02-02_1b3a3b72-e958-49af-99e5-a08da396f496.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2024-01-31

Reporting Person: Smith Jason Drew (General Counsel)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-01-31 Ordinary Shares M 834 Acquired 19241 Direct
2024-01-31 Ordinary Shares S 417 $15.74 Disposed 18824 Direct
2024-01-31 Ordinary Shares M 2500 Acquired 21324 Direct
2024-01-31 Ordinary Shares S 1248 $15.74 Disposed 20076 Direct
2024-01-31 Ordinary Shares M 6666 Acquired 26742 Direct
2024-01-31 Ordinary Shares S 3328 $15.74 Disposed 23414 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-01-31 Restricted Stock Units $ M 834 Disposed Ordinary Shares (834) Direct
2024-01-31 Restricted Stock Units $ M 2500 Disposed Ordinary Shares (2500) Direct
2024-01-31 Restricted Stock Units $ M 6666 Disposed Ordinary Shares (6666) Direct
2024-01-31 Restricted Stock Units $ A 16500 Acquired Ordinary Shares (16500) Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F3: The reporting person was granted RSUs on January 31, 2021 representing 2,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.

F4: The reporting person was granted RSUs on January 31, 2022 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023.

F5: The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.

F6: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027.